Helena Cortez-Pinto

List of Publications by Citations

Source: https://exaly.com/author-pdf/6481047/helena-cortez-pinto-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

 129
 9,547
 41
 97

 papers
 citations
 h-index
 g-index

 165
 13,084
 5.5
 6.43

 ext. papers
 ext. citations
 avg, IF
 L-index

#	Paper	IF	Citations
129	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020 , 73, 202-209	13.4	764
128	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020 , 158, 1999-2014.e1	13.3	748
127	EASL clinical practical guidelines: management of alcoholic liver disease. <i>Journal of Hepatology</i> , 2012 , 57, 399-420	13.4	489
126	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 2184-2196	40	425
125	Hepatic histology in obese patients undergoing bariatric surgery. <i>Journal of Hepatology</i> , 2006 , 45, 600-6	5 1 3.4	401
124	Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. <i>PLoS Medicine</i> , 2014 , 11, e1001680	11.6	363
123	Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. <i>JAMA - Journal of the American Medical Association</i> , 1999 , 282, 1659-64	27.4	348
122	Alcoholic liver disease. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 16	51.1	308
121	EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. <i>Journal of Hepatology</i> , 2018 , 69, 154-181	13.4	298
120	Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. <i>American Journal of Gastroenterology</i> , 2004 , 99, 170	08:77	297
119	Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. <i>Digestive and Liver Disease</i> , 2015 , 47, 997-1006	3.3	279
118	Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. <i>Journal of Hepatology</i> , 2018 , 69, 718-735	13.4	266
117	Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. <i>Journal of Hepatology</i> , 2013 , 58, 1007-19	13.4	259
116	miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2013 , 58, 119-25	13.4	240
115	How different is the dietary pattern in non-alcoholic steatohepatitis patients?. <i>Clinical Nutrition</i> , 2006 , 25, 816-23	5.9	199
114	Non-alcoholic steatohepatitis: from cell biology to clinical practice. <i>Journal of Hepatology</i> , 2006 , 44, 197	7-208	152
113	Bile acid levels are increased in the liver of patients with steatohepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2008 , 20, 519-25	2.2	129

112	Non-alcoholic fatty liver disease: what the clinician needs to know. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12956-80	5.6	117
111	Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis. <i>Clinical Science</i> , 2015 , 129, 721-39	6.5	116
110	Gut microbiota and nonalcoholic fatty liver disease. Annals of Hepatology, 2012, 11, 440-449	3.1	116
109	Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26, 1363	1 ⁴ 7	98
108	Bacterial lipopolysaccharide induces uncoupling protein-2 expression in hepatocytes by a tumor necrosis factor-alpha-dependent mechanism. <i>Biochemical and Biophysical Research Communications</i> , 1998 , 251, 313-9	3.4	96
107	Non-alcoholic steatohepatitis and metabolic syndrome. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2006 , 9, 637-42	3.8	78
106	Activation of necroptosis in human and experimental cholestasis. Cell Death and Disease, 2016, 7, e2390	9.8	76
105	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. Journal of Hepatology, 2020 , 72, 14-24	13.4	75
104	Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2015 , 63, 962-70	13.4	73
103	Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease. <i>Diabetologia</i> , 2011 , 54, 1788-98	10.3	73
102	Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. <i>International Journal of Molecular Sciences</i> , 2016 , 17, 481	6.3	70
101	Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet. <i>Scandinavian Journal of Gastroenterology</i> , 2008 , 43, 95-102	2.4	65
100	Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2006 , 18, 21-9	2.2	64
99	How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 1166-72	2.2	63
98	Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. <i>Hepatology</i> , 2016 , 64, 1388-9	11.2	60
97	Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. <i>Baillierels Best Practice and Research in Clinical Gastroenterology</i> , 2004 , 18, 1089-104	2.5	58
96	Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2012 , 32, 241-8	7.9	55
95	How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. <i>Liver International</i> , 2014 , 34, e111-7	7.9	52

94	Non-alcoholic fatty liver disease and insulin resistance. <i>European Journal of Gastroenterology and Hepatology</i> , 2005 , 17, 823-6	2.2	49
93	miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. <i>Cell Death and Disease</i> , 2017 , 8, e2748	9.8	48
92	Gut microbiota and nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2012 , 11, 440-9	3.1	48
91	Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2017 , 8, 26-38	3	45
90	Treatment and prognostic factors in patients with hepatocellular carcinoma. <i>Liver International</i> , 2006 , 26, 680-7	7.9	42
89	NAFLD - sounding the alarm on a silent epidemic. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 377-379	24.2	41
88	Nonalcoholic steatohepatitisa long-term follow-up study: comparison with alcoholic hepatitis in ambulatory and hospitalized patients. <i>Digestive Diseases and Sciences</i> , 2003 , 48, 1909-13	4	40
87	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. <i>Gut</i> , 2020 , 69, 764-780	19.2	39
86	Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. <i>Hepatology</i> , 2010 , 52, 71-8	11.2	38
85	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	37
84	Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2320-2329.e12	6.9	36
83	Liver and muscle in morbid obesity: the interplay of fatty liver and insulin resistance. <i>PLoS ONE</i> , 2012 , 7, e31738	3.7	34
82	Clinical relevance of liver histopathology and different histological classifications of NASH in adults. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 351-367	4.2	34
81	GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. <i>Journal of Hepatology</i> , 2019 , 70, e5	13.4	33
80	Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH). <i>Annals of Hepatology</i> , 2019 , 18, 518-535	3.1	33
79	Lysosomal acid lipase deficiency: A hidden disease among cohorts of familial hypercholesterolemia?. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 477-484.e2	4.9	33
78	Cell death and nonalcoholic steatohepatitis: where is ballooning relevant?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011 , 5, 213-22	4.2	33
77	Improving dietary patterns in patients with nonalcoholic fatty liver disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2012 , 15, 468-73	3.8	33

(2021-2019)

76	Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: A prospective study. <i>Liver International</i> , 2019 , 39, 1459-1467	7.9	31
75	Insulin resistance and steatosis in chronic hepatitis C. <i>Annals of Hepatology</i> , 2009 , 8, S67-S75	3.1	31
74	Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 54-64.e1	6.9	31
73	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020 , 98, 106175	2.3	28
72	Anticoagulation in Cirrhosis and Portal Vein Thrombosis Is Safe and Improves Prognosis in Advanced Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 2671-2683	4	27
71	What is the relevance of percutaneous endoscopic gastrostomy on the survival of patients with amyotrophic lateral sclerosis?. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2012 , 13, 550-4		27
70	Are genetic polymorphisms of tumour necrosis factor alpha, interleukin-10, CD14 endotoxin receptor or manganese superoxide dismutase associated with alcoholic liver disease?. <i>European Journal of Gastroenterology and Hepatology</i> , 2005 , 17, 1099-104	2.2	25
69	Management of fatty liver disease with the metabolic syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014 , 8, 487-500	4.2	21
68	Liver disease-related admissions in Portugal: clinical and demographic pattern. <i>European Journal of Gastroenterology and Hepatology</i> , 2004 , 16, 873-7	2.2	21
67	Iron homeostasis and H63D mutations in alcoholics with and without liver disease. <i>World Journal of Gastroenterology</i> , 2009 , 15, 106-11	5.6	20
66	Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. <i>European Journal of Gastroenterology and Hepatology</i> , 2002 , 14, 377-81	2.2	19
65	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021 , 75, 770-785	13.4	19
64	The burden of disease and the cost of illness attributable to alcohol drinkingresults of a national study. <i>Alcoholism: Clinical and Experimental Research</i> , 2010 , 34, 1442-9	3.7	18
63	Fatty liver in lean patients: is it a different disease?. Annals of Gastroenterology, 2012, 25, 1-2	2.2	18
62	No need for a large belly to have NASH. Journal of Hepatology, 2011, 54, 1090-3	13.4	17
61	Uncoupling proteins and non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2009 , 50, 857-60	13.4	17
60	Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH). <i>GE Portuguese Journal of Gastroenterology</i> , 2016 , 23, 132-141	1.1	16
59	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 717-729	24.2	16

58	Hepatitis B and C prevalence in Portugal: disparity between the general population and high-risk groups. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, 640-4	2.2	14
57	Skeletal muscle miR-34a/SIRT1:AMPK axis is activated in experimental and human non-alcoholic steatohepatitis. <i>Journal of Molecular Medicine</i> , 2019 , 97, 1113-1126	5.5	13
56	European S NAFLD Preparedness IndexS- Is Europe ready to meet the challenge of fatty liver disease?. <i>JHEP Reports</i> , 2021 , 3, 100234	10.3	13
55	Impact of body weight, diet and lifestyle on nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008 , 2, 217-31	4.2	12
54	The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The,</i> 2021 ,	40	12
53	Anxiety and depression symptoms in hepatic encephalopathy: are they psychiatric or organic?. <i>Transplantation Proceedings</i> , 2015 , 47, 1005-7	1.1	10
52	Genetic polymorphisms of proangiogenic factors seem to favor hepatocellular carcinoma development in alcoholic cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014 , 26, 438-	-43 ²	10
51	Quality of life following liver transplantation: a comparative study between Familial Amyloid Neuropathy and liver disease patients. <i>BMC Gastroenterology</i> , 2009 , 9, 54	3	10
50	Early Rehospitalization Post-Kidney Transplant Due to Infectious Complications: Can We Predict the Patients at Risk?. <i>Transplantation Proceedings</i> , 2017 , 49, 783-786	1.1	9
49	Nutritional support in cirrhotic patients with sarcopenia. Clinical Nutrition ESPEN, 2019, 33, 12-17	1.3	9
48	Body composition and body fat distribution are related to cardiac autonomic control in non-alcoholic fatty liver disease patients. <i>European Journal of Clinical Nutrition</i> , 2014 , 68, 241-6	5.2	9
47	Organ donation and transplantation: a multi-stakeholder call to action. <i>Nature Reviews Nephrology</i> , 2021 , 17, 554-568	14.9	9
46	Waist-to-Hip Ratio is Related to Body Fat Content and Distribution Regardless of the Waist Circumference Measurement Protocol in Nonalcoholic Fatty Liver Disease Patients. <i>International Journal of Sport Nutrition and Exercise Metabolism</i> , 2016 , 26, 307-14	4.4	7
45	Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD. <i>Frontiers in Medicine</i> , 2021 , 8, 683250	4.9	7
44	Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease. <i>Journal of Hepatology</i> , 2021 , 75, 810-819	13.4	7
43	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2021 ,	13.4	7
42	Surgical Complications in Early Post-transplant Kidney Recipients. <i>Transplantation Proceedings</i> , 2017 , 49, 821-823	1.1	6
41	Identifying palliative care needs in a Portuguese liver unit. <i>Liver International</i> , 2018 , 38, 1982-1987	7.9	6

40	Nonalcoholic Fatty Liver Disease versus Alcohol-related Liver Disease: Is it Really so Different?. <i>Current Pharmaceutical Design</i> , 2020 , 26, 1093-1109	3.3	6
39	Waist-to-height ratio is independently related to whole and central body fat, regardless of the waist circumference measurement protocol, in non-alcoholic fatty liver disease patients. <i>Journal of Human Nutrition and Dietetics</i> , 2017 , 30, 185-192	3.1	5
38	The new definition of acute kidney injury in patients with cirrhosis: a critical look. <i>Gut</i> , 2012 , 61, 1513	19.2	5
37	Does the simultaneous tumor necrosis factor receptor 2, tumor necrosis factor promoter gene polymorphism represent a higher risk for alcoholic liver disease?. <i>European Journal of Gastroenterology and Hepatology</i> , 2009 , 21, 201-5	2.2	5
36	Telemedicine as a tool for dietary intervention in NAFLD-HIV patients during the COVID-19 lockdown: A randomized controlled trial. <i>Clinical Nutrition ESPEN</i> , 2021 , 43, 329-334	1.3	5
35	Genetic ancestry analysis in non-alcoholic fatty liver disease patients from Brazil and Portugal. <i>World Journal of Hepatology</i> , 2015 , 7, 1433-8	3.4	4
34	Leptin in the treatment of lipodystrophy-associated nonalcoholic fatty liver disease: are we there already?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013 , 7, 513-5	4.2	4
33	Previous practice of high-intensity sports as a risk factor for non-alcoholic steatohepatitis. <i>Liver International</i> , 2008 , 28, 412-4	7.9	4
32	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance <i>JHEP Reports</i> , 2022 , 4, 100409	10.3	4
31	Prevalence and risk factors of fatty liver in Portuguese adults. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13235	4.6	4
30	Nephrotic Range Proteinuria in Renal Transplantation: Clinical and Histologic Correlates in a 10-year Retrospective Study. <i>Transplantation Proceedings</i> , 2017 , 49, 792-794	1.1	3
29	Predicting short-term and long-term mortality of hospitalized Portuguese patients with alcoholic hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2017 , 29, 1141-1148	2.2	3
28	Proangiogenic factors in the development of HCC in alcoholic cirrhosis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015 , 39 Suppl 1, S104-8	2.4	3
27	Finding the Best Waist Circumference Measurement Protocol in Patients With Nonalcoholic Fatty Liver Disease. <i>Nutrition in Clinical Practice</i> , 2015 , 30, 537-45	3.6	3
26	Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. <i>Baillierels Best Practice and Research in Clinical Gastroenterology</i> , 2004 , 18, 1089-1104	2.5	3
25	Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease. <i>United European Gastroenterology Journal</i> , 2021 , 9, 699-706	5.3	3
24	No Evidence for Lower Levels of Serum Vitamin D in the Presence of Hepatic Steatosis. A Study on the Portuguese General Population. <i>International Journal of Medical Sciences</i> , 2018 , 15, 1778-1786	3.7	3
23	A rare cause of acute liver failure- a case report. <i>BMC Gastroenterology</i> , 2017 , 17, 166	3	2

22	Acute cholangitis in an old patient with Crigler-Najjar syndrome type II - a case report. <i>BMC Gastroenterology</i> , 2016 , 16, 33	3	2
21	What Is the Role of the New Index Relative Fat Mass (RFM) in the Assessment of Nonalcoholic Fatty Liver Disease (NAFLD)?. <i>Obesity Surgery</i> , 2020 , 30, 560-568	3.7	2
20	Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1177-1189	3.4	2
19	A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 929-939	4.2	2
18	What Can We Do When All Collapses? Fatal Outcome of Collapsing Glomerulopathy and Systemic Lupus Erythematosus With Diffuse Alveolar Hemorrhage: Case Report. <i>Transplantation Proceedings</i> , 2017 , 49, 913-915	1.1	1
17	Graft-versus-host disease: unexpected presentation with simultaneous hepatitis and pancreatitis. <i>BMJ Case Reports</i> , 2016 , 2016,	0.9	1
16	Reply to: "Caveats for the implementation of global strategies against non-alcoholic fatty liver disease". <i>Journal of Hepatology</i> , 2020 , 73, 221-222	13.4	1
15	Anticoagulation in patients with cirrhosis and portal vein thrombosis: Safety and beneficial effect on OLT-free survival. <i>Liver International</i> , 2019 , 39, 2002	7.9	1
14	Hepatitis C and metabolic disorders: genetics, mechanism, and therapies (clinical and experimental). <i>International Journal of Hepatology</i> , 2012 , 2012, 937202	2.7	1
13	Are genes really important in alcoholic liver disease?. European Journal of Gastroenterology and Hepatology, 2008 , 20, 1244-8	2.2	1
12	Serum gastrin and gastrin-immunoreactive cells in the antral mucosa of patients with alcoholic liver disease. <i>Apmis</i> , 2000 , 108, 51-6	3.4	1
11	Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 33,	2.2	1
10	Intraductal papillary mucinous neoplasm presenting with recurrent pancreatitis: a report of a painful 3-decade-long history. <i>BMJ Case Reports</i> , 2016 , 2016,	0.9	1
9	Outcomes of excessive alcohol drinkers without baseline evidence of chronic liver disease after 15 years follow-up: Heavy burden of cancer and liver disease mortality. <i>PLoS ONE</i> , 2021 , 16, e0252218	3.7	1
8	Serum vitamin D levels correlate with the presence and histological grading of colorectal adenomas in peri and postmenopausal women. <i>Clinical Nutrition</i> , 2019 , 38, 1390-1397	5.9	0
7	Twenty-Five Years of Increasing Mortality From Pancreatic Cancer in Portugal. <i>Pancreas</i> , 2020 , 49, e2-e	3 2.6	O
6	No evidence of benefit of routine ascitic fluid analysis in refractory ascites undergoing therapeutic paracentesis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 33, 942	2.2	0
5	Alcoholic disease: understanding the scope of the problem and what we need to do to tackle it. <i>Therapeutic Advances in Chronic Disease</i> , 2012 , 3, 53-8	4.9	

LIST OF PUBLICATIONS

Diagnostic Algorithm for the Identification of NAFLD in Primary Care **2020**, 225-234

3	NAFLD Nutritional Management: Results from a Multidisciplinary Approach. <i>GE Portuguese Journal of Gastroenterology</i> ,1-8	1.1
2	Inadvertent oversight while reporting factors predicting decompensation of cirrhosis. <i>Liver International</i> , 2020 , 40, 253	7.9
1	938 Positive Results From REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. <i>American Journal of Gastroenterology</i> , 2019 , 114, S546-S546	0.7